J&J talc users want cancer checks for women even if it cost billions

The suit is the latest salvo in the ongoing legal battle between J&J and former talc users, who allege the world's largest maker of health-care products hid the cancer risks of its iconic baby powder

J&J, Johnson's & Johnson's powder
J&J officials Monday dismissed the proposed class action as a “meritless complaint." | Photo: Bloomberg
Bloomberg
3 min read Last Updated : Jun 18 2024 | 7:49 AM IST
By Jef Feeley
 
Johnson & Johnson should be on the hook for potentially billions of dollars in medical fees for women who used its talc-based baby powders and want to monitor their future health over cancer fears, according to a lawsuit. 
 
Lawyers representing ex-talc users asked a New Jersey federal judge Monday to set up a so-called “medical-monitoring class” to cover the expenses of doctor’s visits and tests for women worried about gynecological and ovarian cancers.

The suit is the latest salvo in the ongoing legal battle between J&J and former talc users, who allege the world’s largest maker of health-care products hid the cancer risks of its iconic baby powder for almost half a century. J&J is seeking the backing from thousands of people who have sued is over the product for an $11 billion settlement of the claims. 

“This kind of monitoring system, especially if covers thousands of women, will be expensive since it goes on for the rest of their lives,” said Carl Tobias, a University of Richmond professor who teaches about mass-tort law. “It could cost J&J hundreds of millions, if not billions, to cover these costs.” 

‘Frivolous’ claim
 
J&J officials Monday dismissed the proposed class action as a “meritless complaint.” Erik Haas, J&J’s lead in-house lawyer on the talc cases, said the suit was another attempt by the plaintiffs to “disseminate false messaging in an effort to thwart their clients from voting on” the company’s proposed settlement.

Such medical-surveillance programmes have been approved in other mass-tort cases, including claims that Dutch manufacturer Koninklijke Philips NA hid flaws in its line of machines designed to treat sleep apnea. The company agreed as part of a $1.1 billion settlement earlier this year to set up a health-monitoring programme for users. 

J&J now faces more than 61,000 lawsuits blaming talc used in baby power and similar products for different types of cancers. Many of those cases have been consolidated before the judge in New Jersey who is overseeing the proposed medical-monitoring class-action case. Other cases are set for trial in state courts.  


Damage verdicts
 
Since 2014, at least a dozen juries have awarded a total of more than $6.5 billion in damages to consumers blaming the powder for their cancers, according to data compiled by Bloomberg News. Many of those awards later were reduced or thrown out on appeal.

J&J maintains its talc-based products don’t cause cancer and it has marketed its baby powder appropriately for more than a century. The company has won a number of cases in court and had other suits dismissed before trial. J&J withdrew its talc-based powders worldwide at the end of 2023 and replaced it with a cornstarch version.

Plaintiffs want the judge to certify a class that covers US women who’ve used talc from 1960 to now, and who haven’t already filed an individual suit. They also want their spouses, parents and dependent children included in the class. 

Former talc users want the judge to order J&J to set up a fund to cover monitoring expenses, including “baseline assessments, diagnostic testing, and preventative measures,” according to the 137-page complaint. 

The case is Bynum v. Johnson & Johnson, 24-cv-07065, US District Court for the District of New Jersey (Trenton). 
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Johnson & Johnson'sJ&Jcancer

First Published: Jun 18 2024 | 7:49 AM IST

Next Story